8 April 2025 - NDA submission includes efficacy and safety data for the first fixed-dose combination therapy from the world’s largest and longest study ever conducted in the presbyopia eye drop category.

Tenpoint Therapeutics today announced that the Company has submitted a new drug application to the US FDA for Brimichol PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the US.

Read Tenpoint Therapeutics press release